per 2 cells in RPMI-1640 containing 10 % FBS, penicillin-streptomycin (50,000 units) and L-glutamine (2 nM) in the presence of inhibitors. Supernatant was evaluated by ELISA as above.
Cell viability and proliferation assessment CD4+ T cells were labeled with 5 µM CFSE (Carboxyfluorescein succinimidyl ester; Molecular Probes) according to the manufacturer's instructions and cultured as above. Before flow cytometry, cells were additionally stained for surface markers (anti-CD4-APC and anit-CD8a-BV510; Biolegend) and viability (fixable viability dye eFluor780; ebioscience). Samples were analyzed on a LSRFortessa (BD Biosciences), and 2 x 10 4 live CD4+ T cells were recorded per sample. Data analysis was performed using FlowJo software (version X 10.0.7). For viability assays, cells were washed twice in cold PBS and stained with anti-Annexin V-APC and 7-AAD (7-Aminoactinomycin D; Biolegend) in Annexin V binding buffer (10x: 10 mM Hepes, pH 7.4, 140 mM NaCl and 2.5 mM CaCl 2 ) for 15 min at room temperature in the dark. Flow cytometry analysis was performed within 1 h of staining in Annexin V binding buffer.
Analysis of STAT phosphorylation by flow cytometry -Phosphoflow 0.5 x 10 6 freshly isolated AS patient PBMC per tested condition were incubated at 37°C and 5 % CO 2 for 20 min with Tofa, Ruxo, Bari, CEP and DMSO control in RPMI-1640. Cells were then stimulated for 15 min with IL-6 100 ng/ml, IFN 40,000 IU/ml, IL-7 50 ng/ml and GM-CSF 50 ng/ml (all Peprotech) under the same conditions. Cells were then immediately put on ice and stained for surface markers (anti-CD3-BV780, anti-CD4-AF700, anti-CD8a-BV510, anti-CD19-BV421; BioLegend, anti-CD14-PE;
Miltenyi Biotec) and viability (fixable viability dye eFluor780; ebioscience) in ice-cold Mean ± SEM, paired t test.
